• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Phathom Pharmaceuticals

< Previous 1 2 3 Next >
News headline image
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
March 26, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
February 29, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
February 13, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
December 14, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers HTGC PHAT
News headline image
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
December 06, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
November 28, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
November 09, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
November 01, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
October 30, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
October 25, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
September 26, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
September 05, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
August 21, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
August 10, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
June 12, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
June 09, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
June 01, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
May 23, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 23, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
May 23, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports First Quarter 2023 Results
May 10, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
May 09, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
April 12, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
April 04, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Provides Regulatory Updates
February 09, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
January 08, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
January 03, 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap